7 Products Boston Scientific is Betting on in 2014: Promus Premier Drug-Eluting Stent

Promus Premier Drug-Eluting Stent

Mahoney says Boston Scientific will look to Premier, which was recently approved and launched in the U.S., to help improve performance of its struggling drug-eluting stent franchise, which saw worldwide sales decline 10% year over year in Q4 2013. Competitive product launches especially hurt Boston Scientific’s drug-eluting stent business in Japan, and Mahoney hopes Premier’s launch and approval in that country this year will help the company regain its leadership position there.





[image courtesy of BOSTON SCIENTIFIC]

Filed Under
500 characters remaining